3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Neoplasms
6
Solid Tumors
2
Skin Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Melanoma
2
Lung Neoplasms
2
Leukemia, B-Cell
2
Head and Neck Neoplasms
2
Breast Neoplasms
2
Vomiting
1
Urinary Bladder Neoplasms
1
Tracheal Diseases
1
TP53 Y220C Mutation
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Synovial
1
Sarcoma, Alveolar Soft Part
1
Sarcoma
1
Salivary Gland Neoplasms
1
Renal Insufficiency
1
Recurrence
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neuroblastoma
1
Nausea
1
Myofibroma
1
Mesothelioma
1
Interventions
Doxorubicin
33
pembrolizumab
16
Gemcitabine
15
eribulin
10
Irinotecan
10
olaratumab
9
Trabectedin
9
pazopanib
8
Docetaxel
8
Injections
7
Cyclophosphamide
7
Nivolumab
6
Fluorouracil
6
anlotinib
5
Temozolomide
5
Ipilimumab
5
Ifosfamide
5
Bevacizumab
5
tazemetostat
4
ridaforolimus
4
Drug Therapy
4
Cetuximab
4
Carboplatin
4
toripalimab
3
surufatinib
3
spartalizumab
3
ganitumab
3
entrectinib
3
conatumumab
3
belinostat
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Sarcoma
×
Tablets
×
Clear all
NCT03016819
2026-02-25
APROMISS
Advenchen Laboratories, LLC
Phase 3
Recruiting
325 enrolled